Table of Contents Table of Contents
Previous Page  307 / 812 Next Page
Information
Show Menu
Previous Page 307 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348

S303

are sex hormones, thyroid hormones and prolactin. However, the

question whether there is an impact of the hormonal distur-

bances on cognitive functioning of schizophrenia patients is rarely

addressed.

Objective

To assess the relationship between serum levels of hor-

mones and cognitive abilities in male schizophrenic patients.

Subjects and methods

In the index group, there were 15

schizophrenia male patients, mean age 36. The control group

was formed by 15 healthy volunteers, mean age 36. In the two

groups, serum hormones levels were measured and neuropsy-

chological tests were performed. Analysed hormones included

thyroid-stimulating hormone (TSH), luteinizing hormone (LH),

follicle-stimulating hormone (FSH), estradiol, testosterone, proges-

terone and prolactin. Cognitive abilities were measured with the

following tests: Trail Making Test (TMT) Part A and B, Semantic

Category Fluency (SCF), Initial Letter Fluency (ILF) and Stroop Task

Part 1 and 2.

Results

The levels of FSH, LH and testosterone were lower in

the index group than in the control group (3.01 mIU/mL vs 5.90

mIU/mL; 3.83 mIU/mL vs 5.28 mIU/mL; 2.76 ng/mL vs 4.69 ng/mL;

accordingly) while the level of prolactin was higher in the index

group (620 uIU/mL vs 118 uIU/mL). Patients performed worse that

controls in all neuropsychological tests. The differences in scores of

TMT Part B, ILF and Stroop Task Part 2were found to be statistically

significant.

Conclusions

There was no significant relationship between

serum level of analysed hormones and performance on cognitive

tasks.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.650

EW533

Reaction time, processing speed and

sustained attention in patients with

schizophrenia: Impact on functioning

A. Orozco

1 , M.

Vicens

1 , A.

Ruiz

1 , A. B

ra˜nas

1 , G.

Lahera

2 ,

1

Príncipe de Asturias university hospital, psychiatry, Alcalá-Madrid,

Spain

2

University of Alcalá- IRyCIS- CIBERSAM, medicine and medical

specialties, Madrid, Spain

Corresponding author.

Introduction

Some studies have related processing speed with

functionality. A more discriminative analysis of different compo-

nents of this neuropsychological construct is needed.

Objectives/Aims

To measure the performance of a group of

patients with schizophrenia in reaction time, processing velocity

and sustained attention. To compare the impact on functioning of

these three measures.

Methods

Ninety-eight outpatients between 18 and 65 years

diagnosed with schizophrenia, based on the DSM-V, with a 3-

month period of clinical stability, were recruited. Sociodemografic

and clinical data were collected: PANSS scale, Akathisia Simpson-

Angus Brief Scale, State-Trait Anxiety Inventory (STAI) and Global

Functioning Scale (GAF). The following variables were measured:

reaction time (SUPERLAB PRO), processing speed (TMT-A, subtest

of symbol coding BACS, verbal fluency) and sustained attention

(Continuous Performance Test).

Results

Functionality of patients was correlated to Elective Reac-

tion Time (the subject must react to different types of stimuli and to

choose between several possible answers) [

P

=

0.205;

P

= 0.047],

but NOT with Simple Reaction Time [

P

= 0.109;

P

= 0.293)]. Func-

tionality was significantly correlated to Symbols Coding (

P

= 0.328;

P

= 0.001), and a trend was observed regarding semantic fluency

(

P

= 0.190;

P

= 0.06) and the TMT-A (

P

=

0.179;

P

= 0.08). InCPT, Cor-

rect Detection was correlated with GAF score (

P

= 0.380;

P

= 0.000)

but not omission errors. The model of lineal regression shows a

differential impact of every measure in global functioning.

Conclusions

Reaction time, processing speed and sustained

attention are different variables and each of them have impact on

functioning in schizophrenia.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.651

EW534

Monotherapy treatment with

cariprazine for the treatment of

predominant negative symptoms of

patients with schizophrenia:

A double-blind, active

comparator-controlled trial

G. Németh

1 ,

, M. Debelle

1

, I. Laszlovszky

1

, E. Szalai

1

,

B. Szatmári

1

, J. Harsányi

1

, Á. Barabássy

1

, S. Durgam

2

, I. Bitter

3

,

S. Galderisi

4

1

Gedeon Richter Plc, medical division, Budapest, Hungary

2

Forest research institute, clinical development, Jersey City, USA

3

Semmelweis university, department of psychiatry and

psychotherapy, Budapest, Hungary

4

University of Naples SAN, psychiatry, Naples, Italy

Corresponding author.

Objective

To examine the effect of cariprazine, a dopamine D

3

/D

2

receptor partial agonist with preferential binding to D

3

receptors,

on predominant negative symptoms of schizophrenia.

Methods

Subjects with schizophrenia and PANSS factor score

for negative symptoms (PANSS-FSNS)

24 and no pseudospecific

factors (e.g. extrapyramidal symptoms, depression) were random-

ized to cariprazine 4.5mg/d (dose range: 3-6mg/d) or risperidone

4mg/d (dose range: 3-6mg/d) for 6 months.

Results

Four hundred and sixty-one patients were randomized

1:1 to double-blind risperidone (

n

= 231) or cariprazine (

n

= 230)

treatment. Change from Baseline (CfB) at week 26 in the primary

parameter, PANSS-FSNS, was larger in the cariprazine group than

in the risperidone group (LSMD =

1.47; 95% CI: [

2.39,

0.53];

P

= 0.002) significant fromweek 14 onwards. CfB at week 26 in the

functional parameter, Personal and Social Performance (PSP) total

score, showed similarly greater improvementwith cariprazine than

risperidone (LSMD = 4.63; 95% CI: [2.71, 6.56];

P

< 0.001) signifi-

cant from week 10 onward. Statistically significant differences in

favor of cariprazine at week 26 were shown in the PSP areas of

self-care, socially useful activities and personal and social relation-

ships. Most patients tolerated the study treatment well, as reflected

by low discontinuation rates due to adverse events (AEs). Adverse

event profiles of cariprazine and risperidonewere similar. Themost

common AEs during study treatment were insomnia (10.0%), and

headache (10.4%), both in the risperidone group.

Conclusion

26-week cariprazine treatment, given as antipsy-

chotic monotherapy, was significantly more effective on negative

symptoms and on functioning than risperidone in patients with

predominant negative symptoms of schizophrenia.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.652

EW535

Identification of subtypes of Chinese

schizophrenia patients before

discharge: A cluster analysis

S. Liu

, Z. Li

Peking Union Medical College, School of Nursing, Beijing, China

Corresponding author.

Introduction

People with schizophrenia is a highly heteroge-

neous group. Identifying subtypes of people with schizophrenia

before discharge may help develop targeted discharge plans.